ENXTPA:STAGR

Stock Analysis Report

Executive Summary

Stallergenes Greer plc, a biopharmaceutical company, engages in the development and commercialization of allergy immunotherapy products and services for diagnosis and treatment of allergies worldwide.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.

Risks

  • Stallergenes Greer has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Stallergenes Greer's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ENXTPA:STAGR

1.4%

FR Pharmaceuticals

-0.3%

FR Market


1 Year Return

49.2%

ENXTPA:STAGR

2.0%

FR Pharmaceuticals

2.7%

FR Market

STAGR outperformed the Pharmaceuticals industry which returned 9.3% over the past year.

STAGR outperformed the Market in France which returned -2.6% over the past year.


Share holder returns

STAGRIndustryMarket
7 Day0%1.4%-0.3%
30 Day0.1%3.2%3.5%
90 Day38.0%0.4%0.6%
1 Year49.2%49.2%5.8%2.0%6.3%2.7%
3 Year49.4%49.4%31.5%17.7%45.3%31.3%
5 Yearn/a13.6%-5.7%59.4%36.0%

Price Volatility Vs. Market

How volatile is Stallergenes Greer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Stallergenes Greer undervalued based on future cash flows and its price relative to the stock market?

56.76x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Stallergenes Greer's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Stallergenes Greer's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Stallergenes Greer is overvalued based on earnings compared to the FR Pharmaceuticals industry average.

Stallergenes Greer is overvalued based on earnings compared to the France market.


Price Based on Expected Growth

Stallergenes Greer is poor value based on expected growth next year.


Price Based on Value of Assets

Stallergenes Greer is good value based on assets compared to the FR Pharmaceuticals industry average.


Next Steps

Future Growth

How is Stallergenes Greer expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

35.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Stallergenes Greer's revenue is expected to grow by 5.9% yearly, however this is not considered high growth (20% yearly).

Stallergenes Greer's earnings are expected to grow significantly at over 20% yearly.

Stallergenes Greer's revenue growth is expected to exceed the France market average.

Stallergenes Greer's earnings growth is expected to exceed the France market average.

Stallergenes Greer's earnings growth is expected to exceed the low risk savings rate of 0.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Stallergenes Greer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Stallergenes Greer performed over the past 5 years?

40.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Stallergenes Greer has delivered over 20% year on year earnings growth in the past 5 years.

Stallergenes Greer has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Stallergenes Greer has become profitable in the last year making it difficult to compare the Europe Pharmaceuticals industry average.


Return on Equity

Stallergenes Greer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Stallergenes Greer used its assets less efficiently than the FR Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Stallergenes Greer has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Stallergenes Greer's financial position?


Financial Position Analysis

Stallergenes Greer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Stallergenes Greer's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Stallergenes Greer's level of debt (4%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Stallergenes Greer's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (222.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 23.4x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 10.7x debt.


Next Steps

Dividend

What is Stallergenes Greer's current dividend yield, its reliability and sustainability?

0.71%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Stallergenes Greer's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Stallergenes Greer's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Stallergenes Greer has not reported any payouts.

Unable to verify if Stallergenes Greer's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Stallergenes Greer has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Stallergenes Greer's dividends in 3 years as they are not expected to pay a notable one for France.


Next Steps

Management

What is the CEO of Stallergenes Greer's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Michele Antonelli (58yo)

0.3yrs

Tenure

0

Mr. Michele Antonelli serves as Chief Executive Officer of Stallergenes Greer plc since January 04, 2019. He has been Director of Stallergenes Greer Plc since December 12, 2018. He served as Executive Vice ...


Management Age and Tenure

1.0yrs

Average Tenure

The average tenure for the Stallergenes Greer management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.9yrs

Average Tenure

58yo

Average Age

The average tenure for the Stallergenes Greer board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Fereydoun Firouz (54yo)

    Executive Officer

    • Tenure: 0.3yrs
    • Compensation: €2.05m
  • Andrew Suchoff

    Global Head of People Operations & Talent Development

    • Tenure: 0yrs
  • Amer Jaber

    Executive Vice President of Operations - Europe

    • Tenure: 0yrs
  • Michele Antonelli (58yo)

    CEO & Director

    • Tenure: 0.3yrs
  • Matthias Vogt

    Chief Financial Officer

    • Tenure: 1.6yrs
  • Youssef Abbas

    Head of Investor Relations

    • Tenure: 0yrs
  • Petr Tor

    Head of Commercial Europe & International

    • Tenure: 0yrs
  • Jérôme Tilly

    Senior Vice President of People Operations – Europe & International

    • Tenure: 0yrs
  • Tibor Nemes

    Executive VP & Head of Americas

    • Tenure: 1yrs
  • Daniel Smith

    Global Head of Information Technology

    • Tenure: 3.1yrs

Board Members

  • Jean-Luc Bélingard (70yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: €75.00k
  • Philip John Broadley (57yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: €51.29k
  • Stefan Meister (53yo)

    Chairman of the Board

    • Tenure: 0.3yrs
  • Rodolfo Bogni (70yo)

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: €60.00k
  • Yvonne Schlaeppi (58yo)

    Independent Non-Executive Director

    • Tenure: 2.9yrs
    • Compensation: €90.00k
  • Elmar Schnee (59yo)

    Lead Independent Director

    • Tenure: 0.8yrs
    • Compensation: €130.00k
  • Michele Antonelli (58yo)

    CEO & Director

    • Tenure: 0.3yrs

Company Information

Stallergenes Greer plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stallergenes Greer plc
  • Ticker: STAGR
  • Exchange: ENXTPA
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €724.213m
  • Shares outstanding: 19.73m
  • Website: https://www.stallergenesgreer.com

Number of Employees


Location

  • Stallergenes Greer plc
  • Tower bridge House
  • St Katharine’s Way
  • London
  • Greater London
  • E1W 1DD
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STAGRENXTPA (Euronext Paris)YesCommon SharesFREURSep 2015
0RB9LSE (London Stock Exchange)YesCommon SharesGBEURSep 2015
STLL.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2015
AA6BST (Boerse-Stuttgart)YesCommon SharesDEEURSep 2015

Biography

Stallergenes Greer plc, a biopharmaceutical company, engages in the development and commercialization of allergy immunotherapy products and services for diagnosis and treatment of allergies worldwide. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/05/16 22:51
End of Day Share Price2019/05/10 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.